Indications for ULTRAVATE:
≥18yrs: apply thin layer to affected areas twice daily for up to max 2 weeks; max 50g/week. Discontinue when control is achieved. Do not occlude.
<18yrs: not established.
Not for oral, ophthalmic, or intravaginal use. Avoid use on the face, scalp, groin, or axillae. Risk of HPA axis suppression with high-potency corticosteroids, prolonged use, application to large surface areas, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Treat infection if present; discontinue until resolved. Reevaluate periodically. Pregnancy. Nursing mothers: avoid nipple/areola area due to infant exposure.
Telangiectasia, application site atrophy, headache; allergic contact dermatitis (discontinue if occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia, glucosuria.
Generic Drug Availability: